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The economic assessment of treatment options in a chronic and severe disease like Psoriatic Arthritis (PsA) is crucial
to estimate the burden of costs. In particular, the impact of new costly medications such as biologic agents have
been studied to figure this important aspect of a multifaceted disease. In a previous observational, longitudinal
multicentre cost evaluation study, the results showed that biologic agents are cost-effective. This study was
obtained from the real clinical practice and encompassed PsA patients refractory to traditional treatments. Similar
data were also obtained from reviews analysis of Randomized Controlled Trials (RCTs). Recently, Cawson et al.
performed a systematic review, network meta-analysis and economic evaluation of biological therapy for the
management of active PsA. The review was conducted to identify relevant, recently published studies and the new
trial data were synthesized, via a Bayesian network meta-analysis (NMA), to estimate the relative efficacy of the
TNF-α inhibitors in terms of Psoriatic Arthritis Response Criteria (PsARC) response, Health Assessment Questionnaire
(HAQ) scores and Psoriasis Area and Severity Index (PASI). In particular the analysis showed that, on average,
etanercept was the most cost-effective treatment and, at the National Institute for Health and Care Excellence
willingness-to-pay threshold of between £20,000 to £30,000, etanercept is the preferred option. This study, as a
systematic review, has been focused on main RCTs on active PsA treated by biological DMARDs and limitations to
this analysis arise from a paucity of data on long-term follow up, as well as radiological progression and long-term
safety. These interesting results reflected the important role of biologic agents in the management of PsA,
highlighting their efficacy and cost-effectiveness. However, there are some unmet needs for pharmacoeconomic
considerations based on prospective and/or on real clinical practice studies, as well as considering all the intriguing
aspects of this challenging disease.Commentary
Psoriatic Arthritis (PsA) is a chronic inflammatory dis-
ease characterized by musculoskeletal and skin manifes-
tations, and variably associated with other extra-articular
manifestations, showing a combination of destructive
changes (joint erosions, tuft resorption, osteolysis) with
bone proliferation (including periarticular and shaft peri-
ostitis, ankylosis, spur formation and non-marginal syn-
desmophytes) [1]. PsA has to be considered a potentially
disabling disease which requires aggressive and continu-
ous treatment; in a prospective study on early PsA, 47%* Correspondence: antonio.spadaro@uniroma1.it
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article, unless otherwise stated.of the patients showed the development of erosive
changes within 2 years of diagnosis [2].
In the context of this complex disease, there is some
evidence showing that peripheral joint involvement is
progressive in the majority of PsA patients [3]. PsA has
showed to be marked by increased disability [4], comor-
bidities [5] and high direct and indirect costs [6]. While
treatment strategies have improved globally some clin-
ical manifestations in recent years, there is still a lack of
consensus regarding the role of traditional Disease-
Modifying Anti-Rheumatic Drugs (DMARDs) in con-
trolling the progression of structural damage, as well as
both in the long-term disease control [7]. The introduc-
tion of new biological molecules, such as etanercept, for
the treatment of PsA has modified the management ofd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ease [8-10]. Nevertheless the role of combination ther-
apy in PsA has been not defined in term of
improvement of effectiveness and safety compared to
biologic monotherapy, even if etanercept showed prom-
ising results when associated to methotrexate [11] or
cyclosporine [12]. Another conflicting issue is the role of
biologic agent in treating predominant axial subset of
PsA, and, for instance, etanercept showed to be effective
in the axial subset of the disease [13].
However, biologic agents are costly medications, not
easily available to all patients with some restriction from
the various Health Systems and private insurances.
Moreover, some PsA patients may experience adverse ef-
fects, and not all patients respond adequately requiring
sometimes the switch to another biologic agent [14].
All these aspects paved the way to pharmacoeconomic
considerations [15] and in the last few years some stud-
ied have been carried out to estimate the burden of costs
of biologic agents. In 2008, an observational, longitu-
dinal multicentre cost evaluation study was carried out
looking at PsA patients refractory to traditional treat-
ment [16]. The results showed that biologic agents are
cost-effective. This study was obtained from the real
clinical practice and encompassed PsA patients refrac-
tory to traditional treatments, assessing retrospectively
for 6 months previously the onset of biologic agents and
prospectively for other 6 months [16].
In a recent issue of the journal [17], Cawson et al. pre-
sented the data from a new economic evaluation sup-
ported by an updated systematic review and meta-
analysis that included recent data for all four TNF-α in-
hibitors (infliximab, etanercept, adalimumab and goli-
mumab) with the aim to determine the relative cost-
effectiveness of all UK licensed for the treatment of ac-
tive, progressive PsA in patients with inadequate re-
sponse to previous DMARDs [17]. The meta-analysis
results were used in a revised economic model which
updates the previous NICE models [18,19] to provide a
cost-effectiveness comparison of all four TNF-α inhibi-
tors. The authors concluded that biologic agents were
cost-effective for treating patients with active PsA com-
pared to traditional treatments. In particular, etanercept
is cost-effective compared to the other biologic treat-
ments [17].
These findings reported by Cawson et al. confirm the
crucial role of all biologic agents in controlling the clin-
ical manifestations of the disease, showing an overall
cost-effectiveness of these medications. Indeed, there are
some limitations from this evaluation related to the type
of analysis based only on RCTs without assessing the
cost-effectiveness in real practice settings. Moreover, the
wide spectrum of the PsA could be a potential bias for
the cost-effectiveness studies. In fact, the heterogeneousclinical spectrum of the disease with a potential predom-
inant pattern of the skin, nail and articular involvements
should be taken into account for the pharmaco-
economic evaluations, since the difficulties to assess
these components by the actual outcome measures
[20-22]. In particular the assessment of nail involvement
[20] and radiographic evaluation of axial features of PsA
[21,22] represent relevant tools in achieving the correct
impact of pharmaeconomic burden of the disease. In
fact, the axial involvement of PsA still represents a chal-
lenge in the management of this intriguing disease and,
potentially, biologic agents are the most effective agents
in treating this subset [23].
Another potential bias of this economic evaluation is
the short term analysis considered and based on RCTs.
Condition such as PsA, chronic by definition and with a
clinical course most of the time characterized by differ-
ent clinical findings, needs to be carefully evaluated in a
long term period of time. At the present a five-year fol-
low up study have been proposed as preliminary data,
based on the real clinical practice (data not shown). In
particular, this study, showing some preliminary data on
a small group of PsA patients encompassing all the wide
spectrum of the disease should be followed by larger
multi-centre studies obtained from the daily outpatients
setting to evaluate all the burden involved in the
management.
Finally, pharmaeconomic analysis of combination
(DMARDs plus TNF alpha blockers) treatment should
be taken into account for a comprehensive estimation of
cost-efffectiveness.Conclusion
At present, studies on cost-effectiveness of biologic
agents in PsA have shown that these medications offer a
good value for money. However, since there are no
head-to-head studies on these biologic medications pub-
lished yet, all the pharmaco-economic evaluations have
been extrapolated from RCTs and just a few longitudinal
studies based on real clinical practice. All the results ob-
tained from these analysis have considered most of the
intriguing aspects of PsA, demonstrating that biologic
agents were effective on either skin and articular compo-
nents of the disease, and cost-effective.
There is still an unmet need in obtaining pharmaco-
economic analysis from a large population of PsA pa-
tients observed for long period of time in real clinical
practice settings.
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